Biotech Startups

Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms. Its products serve clinical fields such as interventional pulmonology and thoracic surgery.

1 investor

Galventa develops delivery technologies for food supplements and over-the-counter products designed to optimize dosage timing and bioavailability. The company focuses on improving the efficacy of nutraceutical formulations through galenic innovation.

1 investor

GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

1 investor

Gamida Cell develops cell therapy treatments designed to expand and enhance cells for therapeutic applications. The company focuses on delivering potentially curative therapies to patients with unmet medical needs.

1 investor

Gamma Diagnostics develops diagnostic tests based on Gamma Prime Fibrinogen (GPF), a blood biomarker for assessing inflammation and predicting cardiovascular and infectious disease outcomes. The company serves clinicians and healthcare providers seeking improved patient risk stratification and treatment planning.

1 investor

GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources that is implanted during brain tumor removal surgery to deliver targeted radiation to remaining cancer cells. It is indicated for patients with operable, newly diagnosed and recurrent brain tumors such as glioblastoma, brain metastases, and meningiomas.

1 investor

Gamow Labs builds an AI system that interprets whole genomes and clinical phenotypes to identify causative variants and produce ACMG-style clinical reports with auditable evidence and treatment recommendations. It serves clinical genetics workflows, focusing on genome interpretation and diagnosis of rare/hard cases.

1 investor

Gan & Lee appears to be a company with significant revenue (4.052 billion reported) and R&D investment activity (1.341 billion CNY), but the page visited does not contain clear information about its core business operations, products, or market focus.

1 investor

Gannet BioChem operates FDA-inspected cGMP manufacturing facilities in Alabama for polymer reagents, activated PEG compounds, and bulk pharmaceutical chemicals, serving research, clinical, and commercial programs at scales from grams to commercial volumes.

1 investor

Ganymede provides a developer-friendly, open-source data platform that integrates and analyzes laboratory data for life science organizations. It helps scientists and developers at biotech and pharmaceutical companies manage lab data and make data-driven decisions across research, development, and manufacturing.

1 investor

Gate2Brain develops therapeutics designed to cross biological barriers, particularly the blood-brain barrier, using a proprietary peptide-based technology platform. The company focuses on biotech drug development for conditions requiring brain delivery.

1 investor

Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.

1 investor

Gavi is a public-private partnership that funds vaccination programs in developing countries through contributions from governments, foundations, corporations, and private donors. The organization mobilizes resources to provide vaccine access and shape vaccine markets in supported nations.

1 investor

Galaxy Brain Scientific develops personalized brain mapping and neuromodulation technologies for research and clinical applications across neurological conditions. The company combines proprietary platform technology for individual brain functional mapping with a non-invasive stimulation system to support precision neuroscience research.

1 investor

GBI Biomanufacturing manufactures stem cells for regenerative medicine applications, including treatments for orthopedic injuries, wound care, and arthritic conditions. The company operates a 40,000-square-foot facility in Plantation, Florida and has expanded its stem-cell production capacity to serve growing demand driven by new state legislation permitting broader clinical use of stem-cell therapies.

1 investor

GREEN VET provides diagnostic testing, health screening, and management services for companion animals, serving veterinarians and pet owners in South Korea. The company operates as a specialized animal healthcare provider offering laboratory diagnostics, digital pathology, and preventive care services.

1 investor

GCS develops advanced biomaterials through proprietary technologies including silk-fibroin fusion materials, RNA hydrogels, and ion-engineered PLLA for scalable real-world applications. The company operates at the intersection of scientific discovery and materials innovation.

1 investor

A South Korean developer of biopharmaceutical products for veterinary use, focused on animal health and welfare through innovative drug development and biopharmaceutical research.

1 investor

Gearbox Biosciences develops Pop-Out-Plasmid (POP) technology, an E. coli platform that produces plasmid DNA and recombinant proteins without antibiotic selection markers or chemical inducers like IPTG, while decoupling growth from production. Its products serve biopharma partners in gene therapy, cell therapy, and vaccine manufacturing, and the technology is available for licensing.

1 investor

Gedea Biotech develops pHyph, an antibiotic-free treatment for bacterial vaginosis and other common vaginal infections aimed at supporting a healthy microbiome. A spin-out from Lund University, the company focuses on women's health and is pursuing partnerships and regulatory approvals in Europe and the US.

1 investor

Gelesis develops an oral superabsorbent hydrogel platform (OHS) built from naturally derived materials that works locally in the GI tract to influence satiety signals and support metabolic health. Its product Plenity is a clinically studied aid for weight management in overweight or obese adults with a BMI of 25 to 40 when combined with diet and exercise.

1 investor

1 investor

GENinCode provides genomic testing for cardiovascular disease prevention and diagnosis using monogenic and polygenic risk assessment to identify patient risk and enable targeted preventive treatment. The company also offers testing for ovarian cancer surveillance, leveraging its proprietary software platform to combine genetic profiles with clinical risk factors.

1 investor

GEn1E is a life sciences company developing next-generation substrate-specific p38α kinase inhibitors to treat rare and inflammatory diseases. It combines a curated database linking genes, pathways, proteins, diseases, and compounds with machine learning models spanning drug discovery through clinical trials.

1 investor